Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 11/20 | 0.84 |
| ▸ | MET | P08581 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8392953 | 1.00 | ALOX5 (0.84) | ALOX5METPKMPTGS1PTGS2 | |
| SCHEMBL17833497 | 0.93 | ALOX5 (0.74) | ALOX5METPTGS1APPMAPT | |
| SCHEMBL10467072 | 0.91 | ALOX5 (1.00) | ALOX5METPKMPTGS1PTGS2 | |
| SCHEMBL10467071 | 0.91 | ALOX5 (1.00) | ALOX5METPKMPTGS1PTGS2 | |
| SCHEMBL3686080 | 0.89 | ALOX5 (1.00) | ALOX5METPKMPTGS1PTGS2 | |
| SCHEMBL30219096 | 0.89 | ALOX5 (1.00) | ALOX5METPKMPTGS1PTGS2 | |
| SCHEMBL9533683 | 0.89 | ALOX5 (1.00) | ALOX5METPKMPTGS1PTGS2 | |
| SCHEMBL29489703 | 0.88 | ALOX5 (0.84) | ALOX5APPMAPTTTRALDH1A1 | |
| SCHEMBL29489695 | 0.87 | ALOX5 (0.83) | ALOX5APPMAPTTTRALDH1A1 | |
| SCHEMBL9534542 | 0.87 | ALOX5 (0.83) | ALOX5APPMAPTTTRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116650898-B | Application of over-expressed alkane hydroxylase gene and laccase gene in LDPE degradation | 天津大学 | 2024-06-25 | — | — | CN | disclosed |
| CN-118028291-A | Application of over-expressed alkane hydroxylase gene and laccase gene in LDPE degradation | 天津大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-116650898-A | Application of over-expressed alkane hydroxylase gene and laccase gene in LDPE degradation | 天津大学 | 2023-08-29 | — | — | CN | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-0717027-B1 | Diarylheptanoide derivative and pharmaceutical composition comprising the same | YAKULT HONSHA KK (JP) | 1999-05-12 | — | — | EP | disclosed |
| US-5763673-A | ENZYME INHIBITORS AND ANTIINFLAMMATORY AGENTS | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1998-06-09 | — | — | US | disclosed |
| EP-0717027-A1 | Diarylheptanoide derivative and pharmaceutical composition comprising the same | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1996-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | ALOX5 25/4885MET 4664/4885PKM 3198/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | ALOX5 25/4885MET 4664/4885PKM 3198/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | ALOX5 10/4885MET 4203/4885PKM 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.